Skip to main menu Skip to main content Skip to footer

Current Studies

Currently Enrolling Studies

Diabetic Macular Edema

CAPRI / EYP-1901-304 / Eyepoint, Inc.

A Phase 3, Multicenter, Prospective, Randomized, Double-Masked, Parallel-Group Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Aflibercept (2 mg) in Participants With Diabetic Macular Edema (DME). Study Details – ClinicalTrials.gov

Neovascular Age-Related Macular Degeneration (nAMD or Wet AMD)

4Front-2 / 4D-150-C004 / 4D Molecular Therapeutics, Inc.

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-1). Study Details – ClinicalTrials.gov

Protocol AO / DRCR Retina Network / Jaeb Center for Health Research

Home OCT-Guided Treatment versus Treat and Extend for the Management of Neovascular AMD. Study Details – ClinicalTrials.gov

Macular Edema Secondary to Inflammation (MESI)

Peak and Pinnacle / KSMP001 / Kodiak Sciences, Inc.

A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants with Macular Edema Secondary to Inflammation (MESI). Study Details – ClinicalTrials.gov

Active Studies – Not Currently Enrolling

Neovascular Age-Related Macular Degeneration (nAMD or Wet AMD)

Ocular SOL / OTX-TKI-2023-AMD-301 / Ocular Therapeutix, Inc.

A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration (nAMD). Study Details – ClinicalTrials.gov

Ocular SOL-R / OTX-TKI-2023-AMD-303 / Ocular Therapeutix, Inc.

A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration (nAMD). Study Details – ClinicalTrials.gov

Daybreak / KS301P109 / Kodiak Sciences, Inc.

A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD). Study Details – ClinicalTrials.gov

Artemis / ADVM-022-12 / Adverum Biotechnologies, Inc.

A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene soroparvovec (Ixo-vec) in Participants with Neovascular Age-Related Macular Degeneration (ARTEMIS). Study Details – ClinicalTrials.gov

4FRONT-1 / 4D-150-C003 / 4D Molecular Therapeutics, Inc.

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-1). Study Details – ClinicalTrials.gov

Geographic Atrophy (GA)

Archer II / ANX007-GA-02 / Annexon, Inc.

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of ANX007 in Participants With Geographic Atrophy (GA). Study Details – ClinicalTrials.gov

For more information on our research studies, please contact Rebecca Ottosen or complete the form found here.

Rebecca Ottosen

ottoser@eyeclinicwi.com
715.261.8572

Contact Our Research Team

For more information on our research studies, reach out to our research staff.

We are here to answer your questions.

contact research staff